Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279061 | 1.00 | MEN1 (0.38) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL14810603 | 0.85 | — | — | |
| SCHEMBL14810597 | 0.85 | — | — | |
| SCHEMBL14810721 | 0.84 | — | — | |
| SCHEMBL14810719 | 0.84 | — | — | |
| SCHEMBL14810582 | 0.83 | PDE2A (0.40) | — | |
| SCHEMBL14810580 | 0.83 | PDE2A (0.40) | — | |
| SCHEMBL14809969 | 0.82 | — | — | |
| SCHEMBL15999433 | 0.82 | — | — | |
| SCHEMBL14810525 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115149-B2 | Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2015-08-25 | — | — | US | claimed |
| US-20140249170-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2014-09-04 | — | — | US | claimed |
| EP-2758376-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS | Vitas Pharma Research Private Limited (IN) | 2014-07-30 | — | — | EP | claimed |
| WO-2013042035-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2013-03-28 | — | — | WO | claimed |
| CN-1197860-C | FAB I inhibitors | SMITHKLINE BEECHAM CORP (CA) | 2005-04-20 | — | — | CN | claimed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | claimed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | claimed |
| CN-1378542-A | Antigen binding fragment I inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | CN | claimed |
| EP-3330269-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS | Vitas Pharma Research Private Limited (IN) | 2018-06-06 | — | — | EP | disclosed |
| US-9115149-B2 | Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2015-08-25 | — | — | US | disclosed |
| US-9115149-B2 | Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2015-08-25 | — | — | US | disclosed |
| US-9115149-B2 | Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2015-08-25 | — | — | US | disclosed |
| US-20140249170-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20140249170-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20080125423-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2008-05-29 | — | — | US | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| CN-1197860-C | FAB I inhibitors | SMITHKLINE BEECHAM CORP (CA) | 2005-04-20 | — | — | CN | disclosed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
| CN-1378542-A | Antigen binding fragment I inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | MEN1 3468/4885NPC1 455/4885ALDH1A1 2491/4885 |
| US-20080125423-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | MEN1 3468/4885NPC1 455/4885ALDH1A1 2491/4885 |
| US-20140249170-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS | FASN, DBI, FAAH | MEN1 4355/4885NPC1 1348/4885ALDH1A1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.